Thank you
This live web event has ended. Thank you for attending.
Description
Learning Objectives
- Review of current cervical cancer screening guidelines in the US.
- Using population-based data, evaluate the risk stratification of cervical precancer and cancer by HPV testing vs cytology screening.
- Identify diagnostic limitations of HPV testing and discuss management of test results near the limit of detection.
Articles
- Cuzick J, Adcock R, et al. 2023. Impact of HPV testing in opportunistic cervical screening: Support for primary HPV screening in the United States. Int J Cancer 153: 83-93.
- Node J, Dor F, et al. 2024. Prevalence and significance of HPV DNA detection below the clinical threshold of the commercial kit Alinity m HR-HPV assay (Abbott). J Med Virol 96:e29465.
Presenters
- Erin Boulanger, Ph.D., Clinical and Public Health Microbiology Fellow, University of Pennsylvania.
- Tristan Grams, Ph.D., Clinical and Public Health Microbiology Fellow, University of Utah/ARUP Laboratories.
Moderator
- Mondraya Howard, Ph.D., D(ABMM), Director of Clinical Microbiology, Penn Medicine Lancaster General Health.
Discussion Panel
- Cynthia Flynn, M.D., Section Chief of Microbiology and Molecular Diagnostics Laboratories, ChristianaCare.
- Dhammika Navarathna, D.V.M., Ph.D., D(ABMM), Clinical Microbiologist, Central Texas Veterans Health Care System.